Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Discoid lupus erythematosus |
French
|
Lupus érythémateux (chronique) |
| Level | Code | Title | |
|---|---|---|---|
| 1 | XII | Diseases of the skin and subcutaneous tissue | |
| 2 | L80-L99 | Other disorders of the skin and subcutaneous tissue | |
| 3 | L93 | Lupus erythematosus | |
| 4 | L93.0 | Discoid lupus erythematosus |
| Active Ingredient | Description | |
|---|---|---|
| Betamethasone |
Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. |
|
| Fluocinonide |
Fluocinonide is a synthetic anti-inflammatory corticosteroid. Its mechanisms of action are related to vasoconstriction and suppression of membrane permeability, mitotic activity, the immune response and release of inflammatory mediators. |
|
| Fluticasone |
Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. |
|
| Hydroxychloroquine |
Hydroxychloroquine is a antimalarial agent with have several pharmacological actions which may be involved in their therapeutic effect in the treatment of rheumatic disease, but its role is not known. |
